Is this your profile?

About

Stephen Allan is a healthcare communication specialist with more than 20 years of expertise across global drug delivery, medical device and nutraceutical markets. After graduating in journalism, he has co-ordinated communication activities for Australian, US and European-based companies. Based in Germany since 2017.

Contributions

INDUSTRIALISATION

FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES

Stephen Allan reviews the history and formulation advantages of lipid nanoparticles (LNPs) and addresses factors that should be considered by pharmaceutical companies during the CDMO selection process to help reduce regulatory risk, improve product performance and accelerate speed to market.

Top